EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Evolution of liver function during immune checkpoint inhibitor treatment for hepatocellular carcinoma

Katharina Pomej iD, Lorenz Balcar iD, Sabrina Sidali, Riccardo Sartoris, Tobias Meischl iD, Michael Trauner, Mattias Mandorfer iD, Thomas Reiberger iD, Maxime Ronot, Mohamed Bouattour iD, Matthias Pinter iD, Bernhard Scheiner iD

United European Gastroenterology Journal · 2024-10 · 12 (8) · 1034-1043

DOI: 10.1002/ueg2.12626 ↗

Kurz gefasst

Fachartikel in der Zeitschrift United European Gastroenterology Journal, online erschienen am 11.07.2024. Verfasst von Katharina Pomej und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Immune Checkpoint Inhibitors, Sorafenib. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Deterioration of liver function is a leading cause of death in patients with advanced hepatocellular carcinoma (HCC). We evaluated the impact of immune checkpoint inhibitor (ICI)‐treatment on liver function and outcomes.

Method

HCC patients receiving ICIs or sorafenib between 04/2003 and 05/2024 were included. Liver function (assessed by Child‐Pugh score [CPS]) was evaluated at the start of ICI‐treatment (baseline, BL) and 3 and 6 months thereafter. A ≥1 point change in CPS was defined as deterioration (−) or improvement (+), while equal CPS points were defined as stable (=).

Results

Overall, 182 ICI‐treated patients (66.8 ± 11.8 years; cirrhosis: n = 134, 74%) were included. At BL, median CPS was 5 (IQR: 5–6; CPS‐A: 147, 81%). After 3 months, liver function improved/stabilized in 102 (56%) and deteriorated in 61 (34%) patients, while 19 (10%) patients deceased/had missing follow‐up (d/ noFU ). Comparable results were observed at 6 months (+/=: n = 82, 45%; −: n = 55, 30%; d/noFU: n = 45, 25%). In contrast, 54 (34%) and 33 (21%) out of 160 sorafenib patients achieved improvement/stabilization at 3 and 6 months, respectively. Radiological response was linked to CPS improvement/stabilization at 6 months ( responders vs. non‐responders , 73% vs. 50%; p = 0.007). CPS improvement/stabilization at 6 months was associated with better overall survival following landmark analysis (6 months: +/=: 28.4 [95% CI: 18.7–38.1] versus −: 14.2 [95% CI: 10.3–18.2] months; p < 0.001). Of 35 ICI‐patients with CPS‐B at BL, improvement/stabilization occurred in 16 (46%) patients, while 19 (54%) patients deteriorated/d/noFU at 3 months. Comparable results were observed at 6 months (CPS +/=: 14, 40%, −: 8, 23%). Importantly, 6/35 (17%) and 9/35 (26%) patients improved from CPS‐B to CPS‐A at 3 and 6 months.

Conclusion

Radiological response to ICI‐treatment was associated with stabilization or improvement in liver function, which correlated with improved survival, even in patients with Child‐Pugh class B at baseline.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsImmune Checkpoint InhibitorsSorafenibHumansMaleFemaleAgedMiddle AgedLiver Function TestsLiverRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

hepatocellular carcinomaimmune checkpoint inhibitorsliver cancerliver cirrhosisliver functionsorafenib

Substanzen

Immune Checkpoint InhibitorsSorafenib

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Liver Cancer (HCC) Study Group Vienna, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Department of Digestive Oncology, APHP.Nord, Hôpital Beaujon, Clichy, France.
  • Department of Radiology, APHP.Nord, Hôpital Beaujon, Clichy, France.
  • Division of Hematology and Oncology, Department of Internal Medicine III, Hanusch Hospital, Vienna, Austria.
  • Université Paris Cité, CRI INSERM U1149, Paris, France.

ORCID-Profile: Katharina Pomej, Lorenz Balcar, Tobias Meischl, Mattias Mandorfer, Thomas Reiberger, Mohamed Bouattour, Matthias Pinter, Bernhard Scheiner

Zitieren

APA

Pomej, K., Balcar, L., Sidali, S., Sartoris, R., Meischl, T., Trauner, M., Mandorfer, M., Reiberger, T., Ronot, M., Bouattour, M., Pinter, M., & Scheiner, B. (2024). Evolution of liver function during immune checkpoint inhibitor treatment for hepatocellular carcinoma. United European Gastroenterology Journal, 12(8), 1034-1043. https://doi.org/10.1002/ueg2.12626

Vancouver

Pomej K, Balcar L, Sidali S, Sartoris R, Meischl T, Trauner M, et al. Evolution of liver function during immune checkpoint inhibitor treatment for hepatocellular carcinoma. United European Gastroenterology Journal. 2024;12(8):1034-1043. doi:10.1002/ueg2.12626

BibTeX
@article{Pomej2024,
  author = {Pomej, Katharina and Balcar, Lorenz and Sidali, Sabrina and Sartoris, Riccardo and Meischl, Tobias and Trauner, Michael and Mandorfer, Mattias and Reiberger, Thomas and Ronot, Maxime and Bouattour, Mohamed and Pinter, Matthias and Scheiner, Bernhard},
  title = {Evolution of liver function during immune checkpoint inhibitor treatment for hepatocellular carcinoma},
  journal = {United European Gastroenterology Journal},
  year = {2024},
  volume = {12},
  number = {8},
  pages = {1034--1043},
  doi = {10.1002/ueg2.12626}
}
Kostenlos starten →